Allogenic islet transplantation (IT) is currently recognized as a key strategy for treatment of brittle type 1 diabetes (T1D).
transdifferentiate in vivo into alpha and then beta cells, following their transplantation in immunocompromised mice. 11 Circulating glucagon level is a biomarker of alpha cell function. 12 CA19-9 (carbohydrate antigen , also called cancer antigen 19-9 or sialylated Lewis a antigen, is normally synthesized by pancreatic ductal cells. 13 In humans, CA19-9
is present in small amounts in serum and increases in several benign or malignant digestive tract disorders. 14,15 CA19-9 is also used as an immunohistochemical marker to identify and fluorescence-activated cell sorting, applied in flow cytometry sort human ductal cells. 9 Here we hypothesized that the presence of ductal cells in islet preparations may serve as trophic factors to enhance the vitality of the graft and the long-term outcome of islet transplantation, possibly through endocrine cell differentiation of ductal cells to beta cells in combination with elevated glucagon values. To confirm this hypothesis, we analyzed the relation between the initial purity of transplanted preparations and graft function during 5 years and studied the kinetics of blood CA19-9 and glucagon levels in parallel with the metabolic results in a consecutive series of 24 recipients of allogenic IT.
| MATERIALS AND METHODS

| Study design
This retrospective study was designed to compare the evolution of graft function and CA19-9 blood levels according to the mean purity (< or ≥50%) of the islet preparations, during 5 years after IT in patients with C-peptide-negative T1D. The subjects were participants in two clinical trials exploring the outcome of IT using the immunosuppressive regimen of the Edmonton protocol both in nonuremic patients with brittle T1D (ClinicalTrial.gov NCT00446264) and uremic patients with previously functioning kidney transplantation (ClinicalTrial.gov NCT01123187). IT in all patients consisted of 2 or 3 sequential infusions of fresh allogeneic islets within 3 months, with the aim of attaining adequate metabolic control (HbA1c ≤ 6.5%) without exogenous insulin. The study protocol was approved by the institutional review board, and a signed informed consent was obtained from each patient.
| Patients
| Pretransplantation characteristics
From the above cohort, 26 patients with T1D had reached 5 years of post-IT follow-up. Two patients were excluded: one patient had a Ca19-9 level above the upper limit of normal (>36 U/mL) before transplantation, and the other relocated and was not available for follow- confirmed by a serum C-peptide ≥0.3 ng/mL in each patient after IT.
These patients were divided into 2 subgroups according to the mean purity of the 2 to 3 islet preparations they had received: <50% (LOW purity) or ≥50% (HIGH purity). The main baseline characteristics of patients in the 2 subgroups are described in Table 1 .
| Islet isolation and transplantation procedure
Pancreata were harvested from ABO-compatible deceased donors and were processed within 12 hours of procurement. Islets were isolated with a slightly modified standard automated method as described previously 3 using purified collagenase, before undergoing isopycnic purification in Biocoll (Biochrom AG Berlin, Germany) gradients with a cell separator (Cobe 2991; Gambro BCT, Lakewood, CO).
Once an islet preparation isolated from a donor was deemed suitable for transplantation (ie, containing >200 000 islet equivalents and/or >3500 islet-equivalents per kilogram of receiver body weight, viability >80%, and volume <8 mL), the recipient was admitted for surgical or radiological implantation of a silicone catheter in the portal tree, under general anesthesia. 16 When necessary, the recipient received 1 or 2 subsequent islet grafts within the next 3 months until >10 000 
| Outcomes
Prospective evaluations were done in each patient at baseline and then yearly until 5 years posttransplantation. These included the following:
(1) clinical and treatment assessment; (2) laboratory measurements; (3) abdominal magnetic resonance imaging (MRI) assessment; (4) continuous glucose monitoring (CGM) profile; and (5) graft function evaluation with β-score. 17 The release characteristics of the mean of the 2 or 3 islet preparations infused in each patient were also recorded, including viability, purity, and the mean number of islets retrieved.
| Methods
| Clinical assessment and treatment of IT recipients
Gender, age, BMI, previous kidney transplantation, and the duration of diabetes were recorded at the time of the first IT. Daily insulin doses and treatment with antidiabetic drugs were recorded before transplantation and yearly for 5 years.
| Laboratory measurements
Assays of the following laboratory parameters were analyzed fasting at baseline and then yearly following the first IT using standardized Its intra-and interassay coefficients of variation were, respectively, 9.4-12.3% and 3.5-12.4%.
| Abdominal MRI assessment
An abdominal MRI (RXH ACHIEVA 1.5T Phillips) was performed before transplantation and yearly after IT. In addition, an abdominal computed tomography (CT) scan was performed in case of CA19-9 >100 IU/L to rule out pancreatic or digestive neoplasia.
| Glucose profile
A daily glucose profile was assessed using CGM (CGMS, Medtronic
MiniMed, Northridge, CA) for 3 consecutive days at baseline, and then yearly following the first IT for 5 years. Glucose profile outcomes included mean glucose, glucose standard deviation around the mean value (standard deviation), and the percentage of time spent in hypo-and hyperglycemia, respectively, <70 and >180 mg/ dL.
| Graft function
Graft function was estimated with the ß-score. The ß-score was calculated as described previously 17 .37
Data are expressed as median (lower -upper interquartile range) unless otherwise specified (gender and kidney graft) %, percentage; CGM, continuous glucose monitoring.
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| Characteristics of the preparations
Each islet preparation was evaluated in triplicate following incubation with dithizone and trypan blue by one experienced islet isolator to determine islet number in islet equivalent and purity, immediately after isolation, as described previously.
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All patients received 2 or 3 islet preparations. In the present study, the total volume of transplanted islets was calculated for each patient as the sum of the number of islet equivalents counted in each preparation he or she received. The mean purity and viability were also calculated for each patient as the mean of individual results of each preparation ponderated by the number of islet equivalents it contained.
| Statistical analysis
All statistical analyses were performed with SAS software (SAS Institute Inc., Cary, NC). Percentage comparisons were performed with chi-square or Fisher's exact tests. Analysis of variance (ANOVA) using the mixed model was used to compare the time trends of the parameters across the 2 groups (LOW and HIGH purity). The ANOVA fixed effects were time, group, and group by time interaction. The subject effect was considered random, and a first-order, autoregressive covariance pattern was chosen to take into account the dependency between the repeated measurements. Associations between quantitative variables were analyzed using the Spearman's correlation coefficient. A P level ≤.05
was considered statistically significant.
| RESULTS
| Purity and metabolic results in islet recipients
Overall, 12 patients (50%) received islet preparations with a mean purity <50%. At baseline the characteristics of islet recipients (islet transplantation alone[ITA] or islet-after-kidney transplantation [IAK], age and duration of diabetes at the time of IT, gender, BMI, blood creatinine and fasting glucose levels, HbA1c, GAD antibodies levels, CGM parameters, and daily insulin need) did not differ between the LOW and HIGH purity groups. Outside of purity, the characteristics of transplanted islets, including mean viability and total islet mass, were also similar between the 2 groups (Table 1) .
Five years after IT the metabolic results were better in the LOW purity than in the HIGH purity groups in terms of daily insulin requirement (9.3 ± 4.0 vs 17.6 ± 4.8 U/day; P = .03) ( Figure 1A ), HbA1c (6.7 ± 0.2% vs 7.3 ± 0.3%; P = .01) ( Figure 1B) , and insulinindependent patients (58% vs 33%; P < .05), with a trend for the β-score (4.5 ± 0.9 vs 3.5 ± 0.8; P = .08). Three patients in each group had no graft function left at 5 years. No abdominal tumor was identified by repeat MRI or CT assessment in the whole cohort.
| Serum CA19-9 levels in islet recipients according to the purity of the islet preparations
Before transplantation, blood CA19-9 levels were normal in all patients, but marginally higher in the LOW purity than in the HIGH purity groups (P = .045). This marginal statistically significant difference resulted from 5 patients, all IAK recipients, with CA19-9 levels in the upper range of normal. It is noteworthy that there was no relationship between CA19.9 level at baseline and its evolution after IT.
A significant difference in the CA19-9 kinetics following IT was observed between the 2 groups, with a bell-shaped curve and higher CA19-9 levels in the LOW purity versus the HIGH purity group (P < .0001) (Figure 2A ). Among the 6 patients who lost islet graft function within 5 years, 3 were ITA recipients in whom immunosuppression could be stopped thereafter. CA19-9 slightly decreased in 2 of them 1 year after the interruption of immunosuppression, whereas it remained stable in the third patient. CA19-9 remained stable after islet loss in IAK patients in whom immunosuppression was maintained for the kidney graft.
Five years after IT, CA19-9 levels in islet recipients were inversely correlated with the purity of islet preparations (r = −0.5; P < .0001),
and not significantly associated with any other parameter.
| Fasting glucagon levels in islet recipients according to the purity of the islet preparations
Before transplantation, fasting glucagon levels did not differ between the LOW purity and HIGH purity groups.
F I G U R E 1 Follow-up of (A) Daily insulin need and (B) HbA1c levels in islet recipients over 5 years according to the mean purity of the islet preps <50% (Low purity) or ≥50% (High purity)
A significant difference in the glucagon kinetics was observed between the 2 groups following transplantation, with higher glucagon levels in the LOW purity versus the HIGH purity groups (P < .0001). The curve was bell-shaped as for the CA19-9 kinetics, especially in the LOW purity group ( Figure 2B ). The glucagon peak accompanied the peak of CA19-9 but appeared slightly delayed at 3 years. Glucagon levels in islet recipients at 5 years were negatively correlated with the purity of islet preparations (r = −0.4; P < .0001),
but not with other parameters. Therefore, glucagon levels, which did not differ between both groups before transplantation, increased significantly in the LOW purity versus the HIGH purity groups after transplantation.
| DISCUSSION
Five years after IT, the metabolic results were better in the LOW purity than in the HIGH purity groups. Over this 5-year period, a significant overall difference in the kinetics of CA19-9 and glucagon was observed between the 2 groups, with higher CA19-9 and glucagon levels in the LOW purity than in the HIGH purity groups. Finally, a strong inverse correlation between CA19-9 levels and purity of the islet preparations was found in the entire study group.
First, we found better 5-year metabolic results in the LOW purity than in the HIGH purity group. Our results are consistent with the inverse relationship between the purity of the islet preparation and graft function assessed by acute insulin response to arginine previously reported at 1 year after IT. 8 Moreover, our results show that this relationship is true up until 5 years after IT using clinically relevant endpoints (daily insulin requirements and HbA1c). Taken together, these results suggest that the presence of nonislet cells in the transplanted preparations may have a favorable effect on IT outcome. Likewise, autologous IT is generally performed with unpurified islet preparations with satisfactory results in terms of metabolic control. [18] [19] [20] Furthermore, insulin independence after allogenic IT from a single donor has been already reported. 7 Subsequently, aiming for a very high degree of purity during islet isolation for allogenic IT could be more deleterious than beneficial.
We next aimed to understand the mechanisms of the potential beneficial effect of the presence of nonislet cells in islet preparations. CA19-9 is an indicator of pancreatic ductal cell presence and/ or proliferation. 9,13-15 Over the 5-year period post-IT, a significant increase of CA19-9 was observed in the recipients, with an overall difference in the kinetics of CA19-9 between the 2 groups: CA19-9 levels were higher in the LOW purity than in the HIGH purity groups.
Moreover, a significant inverse correlation was found between CA19-9 levels and purity of the islet preparations in the entire study group. Taken together with the difference between the 2 groups, this correlation suggests that CA19-9 levels post-IT may be considered a marker of the transplanted mass of ductal cells. Moreover, the secondary increase of CA19-9 suggests that transplanted ductal cells do proliferate in the recipient after IT. Nevertheless, CA19-9
is not absent before IT, and we observed a marginally significantly higher CA19-9 level at baseline in the LOW purity than in the HIGH purity groups. Several mechanisms such as alterations of exocrine pancreas depending on the duration of T1D and exposure to autoantibody levels may contribute to increased CA19-9. 21 There was, however, no difference concerning diabetes duration or GAD levels between the two LOW purity and HIGH purity groups in the present study. This marginal difference appeared related to a higher level of CA19-9 in some IAK patients in the LOW purity group before IT. This fact could be explained by the proliferation of endogenous ductal cells while on immunosuppressants or a reduced creatinine clearance in IAK patients before IT. 22 It is important to note that the evolution of CA19-9 after IT was not correlated with its baseline level. Altogether, the observed increase in serum CA19-9 levels after IT could be considered a surrogate marker for the mass of transplanted ductal cells, meaning the purity of the islet graft, as well as a favorable IT prognosis marker. In addition, the recognition of the expected increase of this marker may obviate the need for repeat morphological investigations seeking pancreatic or digestive cancer in IT patients with high CA19-9 level. 23 Furthermore, it must be noted that CA19-9 levels were not directly correlated with metabolic results. This point raises questions on the mechanisms linking preparation purity (correlated to CA19-9 levels) with better long-term metabolic outcomes in the LOW purity group. Notably, the kinetics of CA19-9 had a bell-shaped curve that peaked at 3 years, raising questions about the fate of ductal cells thereafter. 24 This profile was not influenced by a difference in islet cell loss, the rate of which was similar in the LOW purity and HIGH purity groups. Of interest, glucagon curves also differed between the LOW purity and HIGH purity groups, with the same bell-shape and a peak similar to that of the CA19-9 increase, but slightly delayed in time. These data suggest a possible regeneration F I G U R E 2 Follow-up of blood fasting (A) CA 19-9 and (B) glucagon levels in islet recipients over 5 years according to the mean purity of the islet preps <50% (Low purity) or ≥50% (High purity)
of insulin-producing β-like cells from new pancreatic glucagonproducing cells through continuous mobilization of duct-lining precursor cells in order to adopt an endocrine cell fate, as previously demonstrated. 25, 26 Finally, compared with highly pure preparations, the islet preparations with lower purity, likely enriched in ductal and also in acinar and mesenchymal stem cells, 27, 28 seem to promote long-term beta cell regeneration, possibly due to ductal to alpha to beta cell transdifferentiation. These results confirm the inverse correlation between purity and the quality of AIR previously reported 1 year post-IT. 8 They are also consistent with the experimental demonstration of the in vivo transdifferentiation of human alpha cells following transplantation. 29, 30 Moreover, measuring CA19-9 levels in the clinic is inexpensive and easy, among other biomarkers potentially helpful to predict the outcome of IT.
In conclusion, this study shows a significant impact of the level of purity of the infused islet preparations on long-term metabolic outcome after IT. Lower purity was associated with a better out- Caen Rouen inter-regional network).
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